Judith Versluis
6PUBLICATIONS
57CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (6)
Sort by Publication Date:
|Jan 28, 2026
Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial.Lotte L Hoeijmakers, Petros Dimitriadis, Steven C M A Wijnen
|Oct 01, 2025
Clinical, pathological and molecular characteristics of patients with disease recurrence despite pathologic response to neoadjuvant ipilimumab plus nivolumab in stage III melanoma.Judith M Versluis, Huma Shehwana, Robert Elens
|Apr 27, 2024
Interferon-gamma signature as prognostic and predictive marker in macroscopic stage III melanoma.Judith M Versluis, Stephanie A Blankenstein, Petros Dimitriadis
|Apr 24, 2023
Systemic LRG1 Expression in Melanoma is Associated with Disease Progression and Recurrence.Esmee P Hoefsmit, Franziska Völlmy, Elisa A Rozeman
|Mar 15, 2023
IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma.Irene L M Reijers, Disha Rao, Judith M Versluis
|Apr 27, 2022
Addition of interleukin-2 overcomes resistance to neoadjuvant CTLA4 and PD1 blockade in ex vivo patient tumors.Paulien Kaptein, Celia Jacoberger-Foissac, Petros Dimitriadis
Pageof 1
Frequent Collaborators
5 joint publications
Georgina V Long
4 joint publications
Christian U Blank
4 joint publications
Alexander C J van Akkooi
4 joint publications
Richard A Scolyer
3 joint publications
Petros Dimitriadis
2 joint publications
Irene L M Reijers
2 joint publications
Karijn P M Suijkerbuijk
2 joint publications
Michel W Wouters
2 joint publications
Marta Lopez-Yurda
2 joint publications
Maria Gonzalez
